Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp351 | Osteoporosis: treatment | ECTS2014

A transdermal patch delivering the PTHrP1–34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

Yates John , Alexandersen Peter , Krogsaa Annesofie , Nedergaard Bettina , Clarkin Marcie , Hattersley Gary , Hansen Kris , Karsdal Morten , Christiansen Claus

Abaloparatide (BA058) is a synthetic analog of PTHrP1–34 which greatly increases bone mass and bone strength with preservation of normal bone quality in animal models of osteoporosis. Daily s.c. abaloparatide (ABLSC) at doses of up to 80 μg daily in postmenopausal women with osteoporosis for up to 48 weeks were associated with increases in spine and femoral neck BMD of up to 12.9 and 4.1% respectively and good safety and tolerability. The increa...

ba0006p037 | (1) | ICCBH2017

Early fragility fractures in Zellweger syndrome spectrum – peroxisome dysfunction affecting osteogenesis?

Nicholls Rachel , Pierre Germaine , Chronopoulou Effie , Smithson Sarah F , Offiah Amaka C , Barton John S , Burren Christine P

Background: Peroxisomal Biogenesis Disorders (PBD) is a group of rare metabolic diseases in which peroxisomal function is disrupted. PBD encompasses Zellweger Syndrome Spectrum (ZSS) disorders, which range in severity from classical ZS with severe neurological impairment and markedly reduced life expectancy to Refsum Disease presenting later in childhood. Recent fragility fractures in our ZSS patients in very early childhood prompted case series review.P...

ba0007p185 | (1) | ICCBH2019

High impact exercise to improve musculoskeletal outcomes in Crohn's disease: a feasibility questionnaire

Steell Lewis , Gaya Daniel R , Macdonald Jonathan , Russell Richard K , Seenan John Paul , Wong Sze Choong , Gray Stuart

Objective: Bone and muscle deficits are observed in patients with Crohn’s disease (CD). High-impact exercise (HIE), such as jumping based exercise, can provide hypertrophic and osteogenic stimulus, however to date there have been no studies of HIE in CD. This study aimed to assess the acceptability and feasibility of participating in HIE in adolescents and adults with CD.Methods: Two anonymous questionnaires surveyed adolescents and adults, respecti...

ba0004is22biog | (1) (1) | ICCBH2015

Anorexia nervosa

Misra Madhusmita

Biographical DetailsDr Madhusmita Misra is a full Professor of Pediatrics at Harvard Medical School and a Pediatric Endocrinologist at Massachusetts General Hospital in Boston, Massachusetts. She directs the fellowship training program in Pediatric Endocrinology at Massachusetts General Hospital, and has a Masters in Public Health from the Harvard School of Public Health. Dr M Misra’...

ba0001pp448 | Osteoporosis: treatment | ECTS2013

Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use

Benhamou Claude , De Villiers Tobias , Johnston C Conrad , Langdahl Bente , Saag Kenneth , Denker Andrew , Pong Annpey , McGinnis John P , Rosenberg Elizabeth , Santora Arthur

Relatively little is known about immediate consequences of continuing vs interrupting long-term bisphosphonate treatment. This report describes changes in bone turnover and BMD in a 1-year, dose-finding trial of the calcium-sensing receptor antagonist MK-5442 in postmenopausal, BP-treated women, randomized to continued alendronate 70 mg weekly, switch to placebo, or switch to MK-5442. Recruited women (n=526) had taken alendronate for ≥12 months and an oral BP fo...

ba0002p18 | (1) | ICCBH2013

Influence of anthropometric parameters on assessment of paediatric bone mineral density and bone mineral content

Hangartner Thomas N , Short David F , Gilsanz Vicente , Kalkwarf Heidi J , Lappe Joan M , Oberfield Sharon , Shepherd John A , Zemel Babette S , Winer Karen

Objectives: Creation of reference curves for areal bone mineral density (aBMD) and bone mineral content (BMC) with consideration of relevant anthropometric variables.Methods: Analysis of the dual-energy X-ray absorptiometry (DXA) data collected as part of the Bone Mineral Density in Childhood Study1, including 2012 boys and girls, 5–22 years old, with a total of 10 525 visits, resulting in aBMD and BMC observations at the lumbar spine, hi...

ba0003oc5.2 | Important pathways in bone biology and cancer | ECTS2014

Regulation of bone metastasis by the IKKβ/FoxO3a axis

Marino Silvia , Logan John G. , Sophocleous Antonia , Mollat Patrick , Mognetti Barbara , Ventura Luca , Sims Andrew H. , Rucci Nadia , Ralston Stuart H. , Idris Aymen I.

IκB Kinase β (IKKβ), a key component of NFκB signaling, plays an important role in bone disease and cancer. Genetic and pharmacological inhibition of IKKβ/NFκB signaling increase bone mass and protect against ovariectomy- and inflammation-induced bone loss. Here, we describe a previously unknown role of the IKKβ/FoxO3a axis in bone metastasis associated with breast cancer. We observed that IKKβ expression is prevalent in invasive breast ...

ba0005p21 | Biochemical testing | ECTS2016

Profiles of 25 hydroxyvitamin D and its metabolites 24, 25-dihydroxyvitamin D and 1, 25-dihydroxyvitamin D in vitamin D3 supplementation studies

Tang Jonathan , Nicholls Holly , Dutton John , Piec Isabelle , Washbourne Christopher , Saleh L , Novak A , Close G , Macdonald H , Jackson S , Greeves J , Fraser William

Background: Vitamin D plays an important role in calcium and phosphate homeostasis. Circulating 25 hydroxyvitamin D [25(OH)D] is metabolised into its biologically active form 1,25-dihydroxyvitamin D [1,25-d(OH)D] by the actions of 1α hydroxylase, and into inactive 2metabolite 24,25-dihydroxyvitamin D [24,25-d(OH)D] by 24-hydroxylase. Recent studies suggest the production of 1,25-d(OH)D) from 25(OH)D is 24,25-d(OH)D dependent. Genetic mutations of CYP24A1 gene resulting in...